Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 25, 2025Cancer Immunology Research

Abstract A001: nELISA high-throughput protein profiling applied to the RADIOHEAD cohort: insights from the largest plasma proteomics study of patients receiving checkpoint inhibitor therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEric D. MillerThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research InstituteNRNathaniel RobichaudApplied Bio-nomics (Canada)GOGrant OngoApplied Bio-nomics (Canada)

Discussion

Loading...

Member takes

Implication

This analysis demonstrates the nELISA platform's ability to identify biomarkers in patients, suggesting implications for immunotherapy response and adverse events in cancer treatment.

Key Points

  • The nELISA platform quantified approximately 600 proteins, revealing several biomarkers related to immunotherapy response.
  • Preliminary results show that PD-1 inhibitors increase circulating soluble PD-1 levels, suggesting treatment benefits.
  • Utilizing a prospective design, the RADIOHEAD cohort allows for extensive biomarker discovery through larger sample sizes.
  • Combining nELISA findings with clinical data offers pathways to identify mechanisms of resistance and adverse effects in cancer therapy.

Cite This Study

Miller et al. (2025) studied this question.

synapsesocial.com/papers/68d5dabfddad3c16d4636fc2https://doi.org/10.1158/2326-6074.cimm25-a001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract A002: Comprehensive blood profiling for immunotherapy outcome prediction and longitudinal immune trajectory characterisation2025
  2. 2Data from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study2025
  3. 3Application of comprehensive multi-omic immune profiling strategy achieves superior checkpoint immunotherapy response prediction in lung cancer 35072025
  4. 4Abstract B023: A scalable, proteome-wide protein profiling platform with absolute quantification of 1000 proteins2025 · 1 citations
  5. 5Abstract P73: Elucidating Early Predictive Biomarkers for Immune Checkpoint Blockade (ICB)/Anti-angiogenic Combination Therapy in Advanced Nasopharyngeal Cancer (NPC)2025 · 1 citations